<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896476</url>
  </required_header>
  <id_info>
    <org_study_id>IDE-F1-2021</org_study_id>
    <secondary_id>R44HL147423</secondary_id>
    <nct_id>NCT04896476</nct_id>
  </id_info>
  <brief_title>Prospective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae</brief_title>
  <official_title>Prospective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sonavex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sonavex, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center trial to assess the feasibility and safety of the EchoMark LP and the EchoMark&#xD;
      diagnostic ultrasound system for assessing AV fistula blood flow, diameter, and depth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single-arm, non-blinded clinical trial designed to&#xD;
      evaluate the feasibility and safety of the EchoMark and the EchoSure in subjects undergoing&#xD;
      new upper arm autologous arteriovenous fistula creation who require hemodialysis. All&#xD;
      subjects will provide informed consent prior to undergoing any study procedures. The study&#xD;
      will consists of multiple follow-up visits during the 52 week duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 Days</time_frame>
    <description>Composite of new major device related adverse events (MAEs) at 30 days post EchoMark implantation, as adjudicated by the Clinical Events Committee (CEC) including:&#xD;
Device or procedure-related death&#xD;
Infection requiring EchoMark explantation&#xD;
Fistula failure&#xD;
Fistula rupture&#xD;
Aneurysm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Feasibility Endpoint</measure>
    <time_frame>6 Months</time_frame>
    <description>Rate of Technical Success defined as the successful implantation of the EchoMark implant and the ability to determine blood flow, diameter and depth measurements using the EchoSure diagnostic ultrasound system.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Comparison of EchoSure and duplex measurements of flow</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of EchoSure and duplex measurements of diameter</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of EchoSure and duplex measurements of depth</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time (days to radiographic maturation (date of imaging)</measure>
    <time_frame>6 Months</time_frame>
    <description>defined by 500mL/min and 5mm diameter.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to clinical maturation</measure>
    <time_frame>6 Months</time_frame>
    <description>defined by 75% of sessions with 2-needle cannulation for 4 weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiographic maturation success rate</measure>
    <time_frame>6 Months</time_frame>
    <description>defined by 500mL/min and 5mm diameter, as determined by the physician, and adjudicated by the CEC.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical maturation success</measure>
    <time_frame>6 Months</time_frame>
    <description>defined by 75% of sessions with 2-needle cannulation for 4 weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>6-month patency rate</measure>
    <time_frame>6 Months</time_frame>
    <description>defined by the status (yes/no) of an arteriovenous dialysis access with detectable blood flow through and beyond the anastomosis shown by either an imaging modality or physical examination (presence of a palpable thrill or audible bruit along some point of the arteriovenous dialysis access beyond the arteriovenous anastomosis).</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of events occurring within 30 days of implantation that require reinterventions (open or endovascular), hospitalizations, or prolongation of existing hospitalization.</measure>
    <time_frame>30 Days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of reported reduction of blood flow.</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of the reported inability to cannulate fistula.</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of the development of steal syndrome.</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of bleeding requiring surgical intervention (including PRBC transfusion)</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of infiltration requiring procedural intervention.</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of hematoma requiring procedural intervention.</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of the inability to use the EchoSure component of the system</measure>
    <time_frame>6 Months</time_frame>
    <description>Due to:&#xD;
Migration of the EchoMark device&#xD;
Early resorption of the EchoMark device as defined as breakdown of the EchoMark shape prior to 4 months from index procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of pain associated with the study devices.</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of infection (not limited to infection requiring implant explantation).</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of infection confirmed by either implant explantation or purulent fluid on pathologic assessment during incision and drainage.</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>EchoMark</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo a physician exam prior an arteriovenous fistula creation per the institution's standard of care. After the fistula creation is completed, but prior to closure, the EchoMark will be implanted under the outflow vein.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EchoMark</intervention_name>
    <description>The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.</description>
    <arm_group_label>EchoMark</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or non-pregnant, non-breastfeeding females â‰¥ 18 years of age but &lt; 85 years of&#xD;
             age at the time of informed consent&#xD;
&#xD;
          2. Subject is able and willing to provide written informed consent prior to receiving any&#xD;
             non-standard of care, protocol specific procedures&#xD;
&#xD;
          3. Subject is willing and capable of complying with all required follow-up visits&#xD;
&#xD;
          4. Subject and/or Care Team agree that the distance and transportation resources from the&#xD;
             subject's home to the clinic are reasonable for study participation and compliance&#xD;
&#xD;
          5. Subject has an estimated life expectancy &gt; 18 months&#xD;
&#xD;
          6. Subject is ambulatory (cane or walker are acceptable)&#xD;
&#xD;
          7. Subjects presenting for upper arm autologous arteriovenous fistula creation&#xD;
&#xD;
          8. Vein diameter &gt; 2.5 mm at the antecubital fossa via imaging&#xD;
&#xD;
          9. Artery diameter &gt; 3 mm via imaging&#xD;
&#xD;
         10. Subject is not participating in another investigational clinical trial that has not&#xD;
             met its primary endpoint. Participation in a post-market registry is acceptable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects receiving a forearm fistula.&#xD;
&#xD;
          2. Subject has history of Steal Syndrome.&#xD;
&#xD;
          3. Subject who is immunocompromised or immunosuppressed.&#xD;
&#xD;
          4. Subject has had three previous failed AV fistulae for hemodialysis access&#xD;
&#xD;
          5. Subjects expecting to undergo major surgery within 60 days from the EchoMark&#xD;
             implantation.&#xD;
&#xD;
          6. Known or suspected active infection on the day of the index procedure.&#xD;
&#xD;
          7. Subjects who had infection(s) in the 30-day window prior to EchoMark placement to&#xD;
             reduce the likelihood of partially treated infections that can seed the device and&#xD;
             fistula&#xD;
&#xD;
          8. Subjects with diagnosed bleeding disorder, thrombocytopenia (platelet count &lt;50,000),&#xD;
             hypercoagulability, and history of recurrent deep vein thrombosis not related to AV&#xD;
             access&#xD;
&#xD;
          9. Subjects with active malignancy&#xD;
&#xD;
         10. Subjects with a history of poor compliance with the dialysis protocol&#xD;
&#xD;
         11. Subjects with a known or suspected allergy to any of the device materials&#xD;
&#xD;
         12. Subjects with an existing fistula or graft&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katy Feeny</last_name>
    <phone>443-862-2024</phone>
    <email>kfeeny@sonavex.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

